Hong Kong kicks off COVID-19 vaccinations with Sinovac jab
A million doses arrived in the city last week, and Hong Kong leader Carrie Lam and other top government officials were vaccinated first in a bid to bolster confidence in the program.A poll published in January by the University of Hong Kong found respondents concerned about the Chinese vaccines efficacy.
- Country:
- China
Hong Kong began administering its first COVID-19 vaccines to the public Friday, kicking off its program offering free vaccinations to all 7.5 million residents.
People age 60 and older and health care workers are among some 2.4 million people currently prioritized to receive vaccines at community centers and outpatient clinics across Hong Kong. The government said registrations for the first two weeks of the program are full.
Participants so far will be receiving the vaccine by Chinese biopharmaceutical firm Sinovac. A million doses arrived in the city last week, and Hong Kong leader Carrie Lam and other top government officials were vaccinated first in a bid to bolster confidence in the program.
A poll published in January by the University of Hong Kong found respondents concerned about the Chinese vaccine's efficacy. A panel of Hong Kong experts said the efficacy of the Sinovac vaccine after two doses, 21 days apart, was 62.3 percent. In contrast, a study in Israel found that the two-dose Pfizer-BioNTech vaccine has 92 percent effectiveness.
Hong Kong has since struck deals to buy a total of 22.5 million doses of vaccines, with 7.5 million shots each from Sinovac, AstraZeneca, and Fosun Pharma, which will deliver the Pfizer-BioNTech vaccines to the city.
The government has so far approved the Sinovac and Pfizer-BioNTech vaccines. The first million doses of the Pfizer-BioNTech vaccine were slated to arrive Thursday but have been delayed by export procedures, the government said in a statement.
Local newspaper South China Morning Post reported they were now due to arrive Saturday at the earliest.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Pfizer RSV shot meets goals in trial of high-risk adults under age 60
Health News Roundup: Pfizer RSV shot meets goals in trial of high-risk adults under age 60; Novartis to cut 680 jobs in product development and more
Health News Roundup: Pfizer RSV shot meets goals in trial of high-risk adults under age 60; Cuba says drug use on the rise, especially among youth and more